Hypoxia News and Research RSS Feed - Hypoxia News and Research

Hypoxia is a condition in which there is a decrease in the oxygen supply to a tissue. In cancer treatment, the level of hypoxia in a tumor may help predict the response of the tumor to the treatment.
Lilly receives fourth FDA approval for CYRAMZA (ramucirumab)

Lilly receives fourth FDA approval for CYRAMZA (ramucirumab)

Eli Lilly and Company has received its fourth U.S. Food and Drug Administration approval for CYRAMZA (ramucirumab). CYRAMZA (ramucirumab injection 10 mg/mL solution) is now also indicated in combination with FOLFIRI (irinotecan, folinic acid, and 5-fluorouracil) chemotherapy for the treatment of patients with metastatic colorectal cancer (mCRC) with disease progression on or after prior therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine. [More]
Insulin signaling pathway has significant influence on the growth of glioblastomas

Insulin signaling pathway has significant influence on the growth of glioblastomas

Drugs that target insulin pathways to slow or stop the growth of brain tumors are going in the right direction but appear to be on the wrong track, according to new research at Rice University. [More]
Latest findings regarding nitric oxide offer new avenues to save lives

Latest findings regarding nitric oxide offer new avenues to save lives

Professor Jonathan Stamler's latest findings regarding nitric oxide have the potential to reshape fundamentally the way we think about the respiratory system - and offer new avenues to save lives. It may be time to rewrite the textbooks. [More]
Prevalence of ADHD decreases substantially as altitude increases

Prevalence of ADHD decreases substantially as altitude increases

Recent research has linked the thin air of higher elevations to increased rates of depression and suicide. But a new study shows there's also good news from up in the aspens and pines: The prevalence of attention deficit hyperactivity disorder (ADHD) decreases substantially as altitude increases. [More]
New model can help predict how humans adapt to high- and low-altitude hypoxia

New model can help predict how humans adapt to high- and low-altitude hypoxia

There are few times in life when one should aim for suboptimal performance, but new research at Rice University suggests scientists who study metabolism and its role in evolution should look for signs of just that. [More]
Reoccurring oxygen deprivation during pregnancy affects offspring's liver function

Reoccurring oxygen deprivation during pregnancy affects offspring's liver function

Sleep apnea, a disorder in which breathing repeatedly stops during sleep, is a potentially serious condition because it deprives the body of oxygen. It becomes an even more serious condition in pregnant women—who can be more prone to it—because the oxygen deprivation may affect the baby. [More]
Patients with sickle cell disease have sleep disordered breathing problem

Patients with sickle cell disease have sleep disordered breathing problem

A new study in the Journal of Clinical Sleep Medicine revealed that 44 percent of adults with sickle cell disease who report trouble sleeping actually have a clinical diagnosis of sleep disordered breathing, including sleep apnea, which lowers their oxygen levels at night. [More]
Egalet announces plans to commercialize SPRIX Nasal Spray and OXAYDO tablets

Egalet announces plans to commercialize SPRIX Nasal Spray and OXAYDO tablets

Egalet Corporation, a fully integrated specialty pharmaceutical company focused on developing, manufacturing and marketing innovative pain treatments, today announced its plans for the commercialization of SPRIX (ketorolac tromethamine) Nasal Spray and OXAYDO (oxycodone HCI, USP) tablets for oral use only –CII. [More]
Selten Pharma's SPI-026 granted FDA Orphan Drug Designation for treatment of PAH

Selten Pharma's SPI-026 granted FDA Orphan Drug Designation for treatment of PAH

Selten Pharma, Inc., a privatively held biopharmaceutical company focused on the development and commercialization of therapies for the treatment of rare diseases, announced today that its lead compound tacrolimus (SPI-026) has been granted Orphan Drug Designation by the U.S. Food & Drug Administration for the treatment of pulmonary arterial hypertension (PAH). [More]
Researchers find that exercise may slow tumor growth, improve chemotherapy

Researchers find that exercise may slow tumor growth, improve chemotherapy

One way many cancers grow resistant to treatment is by generating a web of blood vessels that are so jumbled they fail to provide adequate oxygen to the tumor. With oxygen starvation, the tumor gains a sort of cloaking device that protects it from the toxic effects of chemotherapy drugs and radiation, which are designed to seek out well-oxygenated tissue. [More]
Egalet announces net revenues of $1.9 million for 2014

Egalet announces net revenues of $1.9 million for 2014

Egalet Corporation today reported financial results for the year ended December 31, 2014. [More]
New approach could dramatically increase survival rate of cancer patients

New approach could dramatically increase survival rate of cancer patients

Michail Sitkovsky, an immunophysiology expert at Northeastern University, and his research colleagues have made a breakthrough discovery in cancer treatment. The new approach, some 30 years in the making, could dramatically increase the survival rate of patients with cancer, which kills some 8 million people each year. [More]
Study reports 10% reduction in overall C-section births in Portugal

Study reports 10% reduction in overall C-section births in Portugal

A new study reports a significant decline in the rate of cesarean section (C-section) births in Portugal. Findings published in Acta Obstetricia et Gynecologica Scandinavica, a journal of the Nordic Federation of Societies of Obstetrics and Gynecology, indicate a 10% reduction in overall C-section rates between 2009 and 2014, with a 14% reduction in state-hospitals during the same time period. [More]
UT Southwestern researchers find that acetate speeds up growth and metastasis of tumors

UT Southwestern researchers find that acetate speeds up growth and metastasis of tumors

UT Southwestern Medical Center researchers seeking novel ways to combat cancer found that giving acetate, a major compound produced in the gut by host bacteria, to mice sped up the growth and metastasis of tumors. [More]
New findings could pave way to develop drug therapies for necrosis-related diseases

New findings could pave way to develop drug therapies for necrosis-related diseases

Strokes, heart attacks and traumatic brain injuries are separate diseases with certain shared pathologies that achieve a common end - cell death and human injury due to hypoxia, or lack of oxygen. [More]
23andMe announces publication of genome-wide association study of motion sickness

23andMe announces publication of genome-wide association study of motion sickness

23andMe, Inc., the leading personal genetics company, today announced the publication of the first ever genome-wide association study of motion sickness. [More]
Mathematical models of cancer behavior offer new insights on tumor growth

Mathematical models of cancer behavior offer new insights on tumor growth

Hassan Fathallah-Shaykh, M.D., Ph.D., believes that math can transform medicine, and he has the numbers to prove it. [More]
Lilly receives FDA approval for CYRAMZA (ramucirumab)

Lilly receives FDA approval for CYRAMZA (ramucirumab)

Eli Lilly and Company has received its third U.S. Food and Drug Administration approval for CYRAMZA (ramucirumab). [More]
Johns Hopkins researchers discover new way to treat triple-negative breast cancer

Johns Hopkins researchers discover new way to treat triple-negative breast cancer

Triple-negative breast cancer is as bad as it sounds. The cells that form these tumors lack three proteins that would make the cancer respond to powerful, customized treatments. Instead, doctors are left with treating these patients with traditional chemotherapy drugs that only show long-term effectiveness in 20 percent of women with triple-negative breast cancer. [More]
Pembrolizumab shows promising results in patients with classical Hodgkin Lymphoma

Pembrolizumab shows promising results in patients with classical Hodgkin Lymphoma

Merck, known as MSD outside of Canada and the United States, announced today early study findings demonstrating that patients treated with pembrolizumab, the company's investigational anti-PD-1 cancer therapy, achieved an overall response rate of 66 percent, as assessed by International Harmonization Project response criteria (n=19/29: 95% CI, 46-82). [More]
Advertisement
Advertisement